Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086619 · ClinicalTrials.gov registry record · Phase 2
Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
A Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT00086619: Completed Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital.
NCT00086619 is a Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis that has completed, run by Massachusetts General Hospital. The registered enrollment target is 80 participants, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086619, a Phase 2 study of Osteoporosis and Postmenopausal Osteoporosis, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains its ability to improve bone formation, and optional sub-studies will test several potential reasons why PTH's effects on bone formation decline over time.
Primary Outcome
Change from month 0 (pre-treatment) baseline serum aminoterminal propeptide of type I collagen (PINP), osteocalcin (OC), and C-terminal telopeptide (CTX), expressed as an area under the curve (AUC). Each marker measurement result was multiplied by the corresponding subject-specific elapsed study time interval using the trapezoidal rule, and these products were summed to generate a subject-specific AUC (months\*ng/ml) for the marker.
Conditions Studied
Interventions
- DRUG synthetic hPTH 1-34
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00086619 record still lists
NCT00086619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 1,545-participant average among 84 other Osteoporosis trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Osteoporosis appearing as the primary indexed condition, and to 1 intervention - of which synthetic hPTH 1-34 is the first listed.
NCT00086619 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00086619 about?
NCT00086619 is a clinical study titled "Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women". Parathyroid hormone (PTH) increases bone formation and thereby improves bone density and bone strength in postmenopausal women with osteoporosis. However, prolonged PTH treatment increases bone formation less and less over time. This study will test whether increasing the daily dose of PTH sustains ...
What is the current status of trial NCT00086619?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2004-05. Estimated completion is 2009-12.
What conditions does trial NCT00086619 study?
This clinical trial studies the following conditions: Osteoporosis, Postmenopausal Osteoporosis.
What interventions are being tested in trial NCT00086619?
The interventions under investigation include: synthetic hPTH 1-34 (DRUG).
Who is sponsoring clinical trial NCT00086619?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086619 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoporosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00086619's enrollment target sits among peer trials
80 44th of 84 higher than 41 of 84 other Osteoporosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoporosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Acetylcholinesterase Inhibitors on Bone Metabolism
RECRUITING · Phase 2
-
Calcium and Bone Mass in Young Females
COMPLETED · Phase 2
-
Comparison Study of PTHrP and PTH to Treat Osteoporosis
COMPLETED · Phase 2
-
Hormone Replacement Therapy to Treat Turner Syndrome
COMPLETED · Phase 2
-
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
COMPLETED · Phase 2
-
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia